AxoGen, Inc. to Present at the Wedbush Healthcare Conference

Share Article

AxoGen, Inc. to Present at the Wedbush Healthcare Conference

AxoGen Logo

AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is scheduled to present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien in New York, NY.

A live webcast and subsequent archived replay of the Company’s presentation may be accessed via the investor relations section of the Company’s website.

About AxoGen, Inc.

AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

For more information about AxoGen or to sign up for our news alerts, please visit http://www.AxoGenInc.com.

Contact:

EVC Group
Michael Polyviou/Doug Sherk – Investor Relations            
212.850.6020/415.652.9100
mpolyviou(at)evcgroup(dot)com; dsherk(at)evcgroup(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Polyviou/Doug Sherk - Investor Relations
EVC Group
+1 212.850.6020
Email >
Visit website